KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Cost of Revenue (2016 - 2026)

Pacira BioSciences has reported Cost of Revenue over the past 17 years, most recently at $36.4 million for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 6.14% year-over-year to $36.4 million; the TTM value through Mar 2026 reached $151.9 million, down 3.47%, while the annual FY2025 figure was $149.7 million, 12.13% down from the prior year.
  • Cost of Revenue for Q1 2026 was $36.4 million at Pacira BioSciences, down from $40.3 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $61.9 million in Q4 2022 and troughed at $34.3 million in Q3 2025.
  • A 5-year average of $43.6 million and a median of $40.9 million in 2025 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: soared 58.73% in 2022 and later fell 27.65% in 2025.
  • Year by year, Cost of Revenue stood at $61.9 million in 2022, then decreased by 22.97% to $47.7 million in 2023, then decreased by 16.37% to $39.9 million in 2024, then increased by 1.04% to $40.3 million in 2025, then dropped by 9.64% to $36.4 million in 2026.
  • Business Quant data shows Cost of Revenue for PCRX at $36.4 million in Q1 2026, $40.3 million in Q4 2025, and $34.3 million in Q3 2025.